JPH0741402A - Chemical-sustained-release resin molding and its production - Google Patents

Abstract

PURPOSE:To obtain a chemical-sustained-release resin molding capable of holding a large amount of chemical without bleeding it and W releasing it at a constant rate. CONSTITUTION:A resin composition composed of 10-0 pts.wt. thermoplastic resin such as a polyolefin-based resin and 50 to 400 pts.wt., preferably 70 to 200 pts.wt. filler, preferably calcium carbonate is uniaxially or biaxially stretched by a factor of 1.1 to 10. With the resultant porous resin molding, a chemical (e.g. an insecticide, a repellent, a germicide, a fungicide or a perfume) is admixed in an amount of >= saturation dissolution in the resin, thus affording the objective chemical sustained-release resin molding. As the method for admixing the chemical, addition to the resin composition before molding, coating or immersion of the molding before stretching or immersion of the porous molding is used. For controlling the release rate of the chemical-sustained-release resin molding within a more preferable range, in the case where the molding is a sheet or a film, at least one side thereof is coated with a chemical- permeable thermoplastic resin composition layer. In the case of a rod-shaped molding, the outer periphery of the rod-shaped molding is coated therewith.

Description

Detailed Description of the Invention

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a drug sustained-release resin molding and a method for producing the same. More specifically, the present invention relates to a sustained-release drug-molded resin product characterized by holding a large amount of a drug and a method for producing the same.

[0002]

2. Description of the Related Art A method of gradually releasing a drug from a molded product composed of a resin composition in which a drug is uniformly kneaded with a thermoplastic resin has been known in the past. Since the rate of drug release decreases as the amount of drug in the resin decreases as the drug is released into the environment, it has been difficult to maintain a constant rate of drug release. The amount of the drug compatible with the resin varies depending on the selection of the resin and the drug, but is usually as low as about 0.1 to 5% by weight with respect to the thermoplastic resin, and long-term release cannot be expected. It was For example, even if a large amount of the drug having a saturated solubility or more is arranged in the resin composition, in that case, the drug bleeds, or the drug is released in a large amount in the initial stage, so that the drug is still released in a stable manner. There was a problem that it was not enough.

[0003]

DISCLOSURE OF THE INVENTION The present inventors have conducted extensive studies on a sustained-release method for a drug, which contains a large amount of drug without bleeding and can be released at a constant rate. As a result, a resin composition composed of a resin, a filler, and a drug having a saturated dissolution amount or more with respect to the resin is uniaxially or biaxially stretched to make it porous, so that a large amount of drug can be retained and a constant rate of release performance The present invention has been completed by finding that a drug-releasing resin molded product can be obtained.

[0004]

That is, the present invention is as follows. A resin composition comprising 100 parts by weight of a thermoplastic resin and 50 to 400 parts by weight of a filler is uniaxially or biaxially 1.1 to 1
1. A drug sustained-release resin molded product, which comprises a porous resin molded product obtained by stretching at a draw ratio of 0 and containing an amount of a drug having a saturated solubility or higher in a thermoplastic resin. A resin composition comprising 100 parts by weight of a thermoplastic resin, 50 to 400 parts by weight of a filler, and a drug in an amount equal to or more than the saturated solubility in the thermoplastic resin is uniaxially or biaxially 1.1 to 1
2. A method for producing a drug sustained-release resin molded product, which comprises stretching at a ratio of 0 to make it porous. A resin composition consisting of 100 parts by weight of a thermoplastic resin and 50 to 400 parts by weight of a filler is uniaxially or biaxially stretched 1.1 to 10 times in a state of being immersed in the drug or coated with the drug to make it porous. 3. A method for producing a drug sustained-release resin molded product, which is characterized by: A resin composition comprising 100 parts by weight of a thermoplastic resin and 50 to 400 parts by weight of a filler is uniaxially or biaxially 1.1 to 1
To provide a method for producing a drug sustained-release resin molded product, characterized in that a porous resin molded product obtained by stretching at a draw ratio of 0 contains a drug in an amount equal to or more than a saturated dissolution amount in a thermoplastic resin. is there.

The thermoplastic resin used in the present invention is, for example, at least one selected from α-olefin homopolymers such as low density polyethylene, high density polyethylene, polypropylene and polybutene, and α-olefins having 3 to 18 carbon atoms. Of α-olefin and ethylene, copolymers of propylene and ethylene and / or butene-1, ethylene and vinyl acetate and / or ethylenic unsaturated bonds such as acrylic acid ester / methacrylic acid ester Examples thereof include polyolefin resins such as a copolymer with an organic carboxylic acid derivative. These may be used alone or in combination of two or more. Among these resins, a copolymer of ethylene with at least one α-olefin selected from α-olefins having 3 to 8 carbon atoms is preferable from the viewpoint of strength at the time of compounding the filler, and is a thermoplastic resin component. At least 20% by weight or more has 4 carbon atoms
A linear low density polyethylene which is a copolymer of ethylene with at least one α-olefin selected from α-olefins having a density of 0.870 to 0.915.
Those having g / cm ³ are more preferable from the viewpoint of drawability at low temperature.

In the present invention, the amount of the filler is usually 50 to 400 parts by weight based on 100 parts by weight of the thermoplastic resin. When the amount of the filler is less than 50 parts by weight, the total volume of the fine pores occupying the resin body made porous after stretching is insufficient, and when it exceeds 400 parts by weight, the workability is deteriorated, which is preferable. Absent. Particularly, from the viewpoint of processing stability, the filler is preferably 70 to 200 parts by weight.

Examples of the filler used in the present invention include carbonates such as calcium carbonate, magnesium carbonate and barium carbonate, sulfates such as barium sulfate, magnesium sulfate and calcium sulfate, and phosphates such as magnesium phosphate and calcium phosphate. Hydroxides such as magnesium hydroxide and aluminum hydroxide, oxides such as alumina, silica, magnesium oxide, calcium oxide, zinc oxide and titanium oxide, chlorides such as zinc chloride, iron chloride and sodium chloride, aluminum powder, Inorganic fillers such as zeolite, shirasu, clay, diatomaceous earth, talc, carbon black, and volcanic ash, and wood powder, cellulose powder such as pulp powder, nylon powder, polycarbonate powder, polypropylene powder,
Mention may be made of synthetic resin powders such as poly-4-methylpentene-1 powder and organic fillers such as activated carbon, chitosan powder, chitin powder and starch, which may be used alone or in combination. Flexibility of drug sustained-release resin molding,
From the viewpoint of appearance and the like, calcium carbonate is particularly preferable as the filler. The filler is preferably used because the filler having an average particle diameter of 1 to 100 μm has excellent dispersibility and a homogeneous porous body can be obtained, so that the drug release rate from the drug sustained-release resin molded product becomes uniform. .

The drug sustained-release resin molded product of the present invention can hold a drug having a saturated solubility or more in a thermoplastic resin. The upper limit of the amount of the drug depends on the amounts and types of the thermoplastic resin, the drug, and the filler to be used, and is not particularly limited, but if the amount is too large, bleed out occurs, so the upper limit is usually the thermoplastic resin 100. It is up to about 350 parts by weight with respect to parts by weight. The porous drug sustained-release resin molded product of the present invention comprises microvoids (fine pores) obtained by stretching, and the microvoids are non-independent pores and have through-holes, and the drug is contained therein. Therefore, even if the amount of the chemical agent equal to or more than the saturated dissolution amount of the thermoplastic resin is present in the resin molded body, the bleed-out phenomenon on the surface does not occur. The saturated dissolution amount with respect to the thermoplastic resin referred to here is the maximum amount of the drug that can be absorbed by the resin when the resin is immersed in the drug (in the present invention,
For convenience, it means the value measured at 23 ° C.). The drug is 23
When it is a solid at ℃, the resin and the drug are mixed in a state of being heated and melted, and when the drug is cooled to 23 ° C. and left to stand, the drug does not crystallize inside the resin or on the resin surface. It means the maximum amount that can be uniformly dispersed in the resin.

Since the drug sustained-release resin molded product of the present invention can release various drugs depending on the purpose, the drug used in the present invention is not particularly limited, but the drug that can be used is an insect repellent. , Antifungal agent, repellent, bactericide, rust inhibitor,
At least one or more agents arbitrarily selected from the group consisting of aromatic agents and essential oils obtained from plants and the like can be mentioned.
The drug as used herein refers to an active ingredient or its preparation. More specifically, examples of the drug used in the present invention include insect repellents such as permethrin, allethrin, d-allethrin, dd-allethrin, plaresulin, cyphenothrin, d-phenothrin, d-resmethrin, enpentrin, fenvalerate, and phen. Pyrethroid insecticides such as propasulin, cyhalothrin, cyfluthrin, etofenprox, tralomethrin, benfluthrin, terralesulin, and phenothrin, organophosphorus insecticides such as fenitrothion, dichlorvos, naredo, fenthion, siaphos, chlorpyrifos, diazinon, and calclofos, methoxydiazo. Insecticides such as benzene, propoxur, fenobucarb, carbamate insecticides such as carbaryl, pyriproxyfen, mesoprene, hydroprene, diflubenz Down, cyromazine, phenoxy curve, Rufenyuron (CGA18459
Insect growth regulators such as 9). Examples of these compounds that enhance the effect of the insect repellent include piperonyl butoxide, MGK264, octachlorodipropyl ether and the like, which can be used in combination with the above insect repellent. Examples of pest repellents include diethyltoluamide, dibutyl phthalate and the like. Examples of the mildew-proofing agent include dehydroacetic acid, 4-isopropyl-m-cresol, benzyl n-butyl phthalate, and allyl isothiocyanate. Examples of the bactericide include cresol and resorcin. Examples of plant essential oils include hinoki cypress essential oil, hiba essential oil, moon peach essential oil, mustard extract oil, wasabi extract oil, and the like.Some of these plant essential oils also have activities such as insect repellent and mildew proof in addition to aroma action. Therefore, depending on its medicinal effect and activity, it may be used not only as an aromatic agent but also as an insect repellent or a fungicide.

As one of the ordinary methods for obtaining the drug sustained-release resin molded product of the present invention, first, a thermoplastic resin, a filler, and a drug in an amount equal to or more than the saturated solubility in the thermoplastic resin are added, if necessary. Is mixed or kneaded with a dispersant, a stabilizer and the like by a usual method using a roll type or Banbury type kneader or a single-screw or twin-screw extruder to obtain a composition. Then, this composition is usually used in the form of a sheet having a thickness of 30 μm to 10 mm and a diameter of 30 μm to 1 mm.
It is usually molded into a rod-shaped body of 0 mm and molded into 1
In the range of 0 to 140 ° C, more preferably 20 to 140 ° C
By uniaxially or biaxially stretching at a ratio of 1.1 to 10 times within the above range, a drug sustained-release resin molded body is obtained.
The preferred stretching temperature varies depending on the resin composition, but if the stretching temperature is less than 10 ° C, the stability during stretching is unfavorable.
If the temperature exceeds 40 ° C, microvoids are less likely to occur, which is not preferable. As the stretching method, in the case of uniaxial stretching, a roll stretching method or a stretching method using a drawing die is usually used. In the case of biaxial stretching, simultaneous biaxial stretching is possible, or sequential biaxial stretching in which transverse stretching is carried out after longitudinal stretching is possible. The draw ratio is usually 1.1-
The range is 10 times. When the draw ratio is less than 1.1 times, the porosity (the ratio of the total volume of the fine pores per unit weight of the resin molded body) becomes low, and the inside of the resin molded body after stretching is
The drug bleeding out from the resin cannot be stably present. On the other hand, if it exceeds 10 times, the resin will be broken or the diameter of the fine pores will be unnecessarily increased, so stretching at a draw ratio in the above range is preferable. The molded product obtained by stretching can be used as it is,
If necessary, annealing is also performed to suppress post-shrinkage. The annealing temperature is preferably between the stretching temperature and the melting point of the resin.

When the drug is a liquid, it can be used as it is or diluted with a volatile or non-volatile solvent to prepare a resin composition before stretching. When the drug is a solid, it can be used. Alternatively, the drug may be mixed as it is with the resin and the filler and stretched, or the drug may be dissolved in a volatile or non-volatile solvent before use. In addition, if the chemicals cannot be mixed with the resin and the filler in advance because the chemicals are volatilized or decomposed by heat processing, the thermoplastic resin and the filler, and if necessary, the dispersant and the stabilizer are roll type. Alternatively, a composition is obtained by mixing or kneading by a usual method using a Banbury type kneader or a single-screw or twin-screw extruder. Then, this composition is usually used in a sheet shape of 30 μm to 10 mm and a diameter of 30 μm
A drug sustained-release resin obtained by forming a rod-shaped body having a diameter of 10 mm into a drug or a liquid in which the drug is dissolved in a volatile solvent, or stretching the rod-shaped product with the drug or its solution applied. A molded body is obtained. In this method, the drug sustained-release resin molded product of interest is obtained by incorporating the drug into the microvoids (fine pores) formed during stretching. The drug sustained-release resin molded product of the present invention comprises 100 parts by weight of a thermoplastic resin and 50 to 4 fillers.
A porous resin molding obtained by stretching a resin composition consisting of 100 parts by weight at a ratio of 1.1 to 10 is immersed in a drug or a solution thereof, or the drug or a solution thereof is dropped into the porous resin molding. It can also be produced by a method in which a drug is contained in an amount equal to or more than the saturated dissolution amount in the thermoplastic resin.

In the drug sustained-release resin molding of the present invention, in order to control the drug release rate within a more preferable range, 100 parts by weight of a thermoplastic resin and 50 to 400 fillers are used.
A resin composition obtained by arranging a thermoplastic resin composition on at least one side of a resin composition consisting of parts by weight and a drug having a saturated solubility in a thermoplastic resin or more, is uniaxially or biaxially stretched at a ratio of 1.1 to 10 It can also be obtained by doing. For the same purpose, a drug-permeable thermoplastic resin composition layer is attached to at least one surface of a drug sustained-release resin molded product comprising a drug and a porous resin molded product containing the drug by a method such as lamination. Also by this, a drug sustained-release resin molded product can be obtained. In the case of producing a rod-shaped drug sustained-release resin molded product, a resin composition comprising 100 parts by weight of a thermoplastic resin, 50 to 400 parts by weight of a filler, and a drug in an amount equal to or more than a saturated dissolution amount with respect to the thermoplastic resin. A drug-controlled release resin molded product can be obtained by stretching a resin composition having a thermoplastic resin composition layer permeable to a drug on the outer peripheral portion thereof at a ratio of 1.1 to 10. Alternatively, the rod-shaped drug sustained-release resin molded article may be immersed in a solution in which a thermoplastic resin is dissolved in a solvent, and the thermoplastic resin may be disposed on the outer peripheral portion of the rod-shaped object by evaporating the solvent after pulling up. it can.

Examples of the thermoplastic resin composition arranged for such purpose include, for example, α-olefin homopolymers such as low density polyethylene, high density polyethylene, polypropylene and polybutene, and α-olefins having 3 to 18 carbon atoms. A thermoplastic resin such as a copolymer of at least one α-olefin selected from ethylene and ethylene, a copolymer of propylene and ethylene and / or butene-1 or a mixture of two or more thereof is used. Alternatively, with these thermoplastic resins, calcium carbonate, magnesium carbonate, carbonates such as barium carbonate, barium sulfate, magnesium sulfate, sulfates such as calcium sulfate,
Phosphates such as magnesium phosphate and calcium phosphate, hydroxides such as magnesium hydroxide and aluminum hydroxide, alumina, silica, oxides such as magnesium oxide, calcium oxide, zinc oxide and titanium oxide, zinc chloride, iron chloride, Chlorides such as sodium chloride, aluminum powder, zeolite, shirasu, clay, diatomaceous earth, talc, carbon black, inorganic fillers such as volcanic ash and wood powder, cellulose powder such as pulp powder, nylon powder, polycarbonate powder, polypropylene powder, It may be a mixture with a synthetic resin powder such as poly-4-methylpentene-1 powder, starch chito acid, chitin powder, or an organic filler such as activated carbon. Such a resin or a thermoplastic resin composition layer comprising a resin and a filler does not completely block the permeation of the drug but has the property of allowing the drug to permeate. The type of resin, the thickness of the resin layer, the filler The rate of drug permeation can be controlled by controlling the selection of the above to control the sustained release rate of the drug.

[0014]

When the drug used in the present invention has a certain vapor pressure (1 × 10 ⁻⁵ to 1 × 10 ² mmHg), the drug is removed from the resin portion in the molded article and the microvoids exposed on the surface. It is released by evaporation. Regarding the resin portion, the saturated dissolution amount of the resin is present in the initial state,
When drug release begins, a concentration gradient occurs between the release surface and the inside of the resin molding, but since there is a large amount of drug in the microvoids, the drug is supplied from the microvoids to the resin part and eventually equilibrates. Reach the state. This equilibrium state continues until the drug in the microvoids is exhausted,
During that time, the release rate is constant. For drugs with a fairly low vapor pressure (vapor pressures below 1 × 10 ⁻⁵ mmHg),
The amount of drug released from the surface of the resin molded body due to evaporation is extremely small, but the drug is directly adsorbed from the surface of the resin or microvoids by contact or indirectly adsorbed through a medium, and thus the surface of the resin or microvoids. When the drug is lost and the surface concentration decreases, the drug is supplied from the microvoids and the surface concentration is kept constant, as in the above case, and the sustained release amount of the drug is substantially constant. can do.

[0015]

INDUSTRIAL APPLICABILITY The drug sustained-release resin molded product of the present invention is excellent in retaining a large amount of drug, and is suitable for releasing the drug at a constant rate or at a constant amount. ,
Anti-rust agent, aromatic and extremely useful as a drug sustained-release resin molded product of a drug such as essential oil obtained from plants, due to the nature of the drug used, the resin molded product of the present invention, insect repellent, mildew-proof, sterilization, It can be used for rust prevention or as a fragrance.

[0016]

EXAMPLES The present invention will now be described in detail with reference to examples, but the present invention is not limited thereto. The methods for measuring physical properties and the efficacy evaluation tests shown in Examples and Comparative Examples are as follows. Saturated dissolution amount: Thermoplastic resin 50 x 50 x 0.5 mm
The sheet formed into a sheet was dipped in a drug at 23 ° C, and the amount of drug absorbed per unit weight of resin when the absorption of the drug into the resin reached saturation after a certain period of time was taken as the saturated dissolution amount. Is. Drug release amount: The drug release amount from the drug sustained-release resin molded product was measured by using the drug sustained-release resin molded product as a test piece having a size of 4 cm × 10 cm (release area: 80 cm ² ) in a constant temperature bath at 40 ° C. The amount of the drug in the molded article was hung and examined by changing the weight, and the transpiration rate of the drug from each test piece was determined by the following formula and shown in Tables 3 and 4 and FIGS. Evaporation rate (%) = (amount of drug released after a certain period of time) / (initial amount of drug) x 100 Bleed-out property: The presence or absence of bleed-out of the drug on the surface of the drug sustained-release resin molding was visually observed and evaluated. . Efficacy evaluation test method a) Initial efficacy evaluation Specimens: German cockroach (Blattella germanica) adult (sex ratio = 1); Yellow termite (Coptotermers formosanus); Worker fleas (Ctenocephalides felis)

Test method: 10 test insects in a group of 10 were released on each resin agent sustained-release resin molded product, and the number of knockdown insects was observed every 120 minutes at a predetermined time. KT50 (50% of the test insects was The time required to knock down) was calculated. In addition, lethality was observed after 3 days in cockroaches, 1 day after in termites, and 1 day after in fleas, and the lethality rate (%) was calculated. Each was repeated 3 times. The results are shown in Table 3. The size of the drug sustained-release resin molding used in each test is as follows. Against cockroaches (15 x 15 cm) Against termites (7.5 x 7.5 cm) Against fleas (7.5 x 7.5 cm)

B) Evaluation of persistence of efficacy Test method: Rubbing the surface of each of the reagent controlled release resin moldings with gauze impregnated with ethanol to wipe off the drug on the surface of the drug controlled release resin molding, and then at room temperature. The test was conducted in the same manner as in the initial efficacy evaluation by allowing the solution to stand for one day under the conditions to completely volatilize ethanol and stabilize the drug concentration on the surface of the drug sustained-release resin molded product. The results are shown in Table 4.

Example 1 100 parts by weight of linear low-density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Excellen VL VL200) as a thermoplastic resin and calcium carbonate (manufactured by Shiraishi Calcium Co., Ltd.) as a filler, Trade name: Whiten SSB (red) 120 parts by weight and Empentrin (Sumitomo Chemical Co., Ltd., trade name: Vaporthrin) 55 parts by weight as a medicine by using a Banbury mixer 1
The resin composition was obtained by kneading at 20 ° C. for 5 minutes. This resin composition was formed into a sheet having a thickness of 1 mm by T-die molding using an extruder, and this sheet was stretched at a temperature of 50 ° C. by a factor of 4 in a uniaxial (MD) direction to obtain a drug sustained-release resin molded body. The obtained drug sustained-release resin molded product had good processability and had excellent performance without bleeding out of the drug on the surface of the drug sustained-release resin molded product.

Example 2 A drug sustained-release resin molding was obtained in the same manner as in Example 1, except that phenothrin (Sumitomo Chemical Co., Ltd., trade name: Smithlin) was used as the drug. The drug sustained-release resin molded article had good processability and had excellent performance without bleeding out of the drug on the surface of the drug sustained-release resin molded article.

(Example 3) 20 parts by weight of linear low density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Excellen VL VL200) as a thermoplastic resin and linear low density polyethylene (manufactured by Sumitomo Chemical Co., Ltd.) , Trade name: Sumikasen α CS3003) 60 parts by weight and low density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., Trade name: Sumikasen F20
8-0) A drug sustained-release resin molding was obtained in the same manner as in Example 1 except that 20 parts by weight was used. The drug sustained-release resin molded article had good processability and had excellent performance without bleeding out of the drug on the surface of the drug sustained-release resin molded article.

Example 4 100 parts by weight of linear low-density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Excellen VL VL200) as a thermoplastic resin and calcium carbonate (manufactured by Shiraishi Calcium Co., Ltd.) as a filler, 120 parts by weight of product name: Whiten SSB (red) was kneaded with a Banbury mixer at 120 ° C. for 5 minutes to obtain a resin composition. This resin composition was subjected to T-die molding by an extruder to form a sheet having a thickness of 1 mm, and the obtained sheet was immersed in an empentryin solution and stretched 4 times in a uniaxial direction at 50 ° C. by a roll stretching machine to gradually release the drug. An extruded resin molding was obtained. The drug adhering to the surface of the sheet was wiped off, and the content of empentrin in the drug sustained-release resin molded product was measured.
It was 5 parts by weight. The drug sustained-release resin molded article had good processability and had excellent performance without bleeding out of the drug on the surface of the drug sustained-release resin molded article.

(Example 5) Low density polyethylene (Sumitomo Chemical Co., Ltd., trade name: Sumikasen G801) as a thermoplastic resin was laminated on both sides of the porous body obtained in Example 1 to a thickness of 50 μm. To obtain a drug sustained-release resin multilayer body. The obtained drug sustained-release resin multilayer body had excellent performance without bleeding out of the drug on the surface of the drug sustained-release resin molded product.

Example 6 A linear low density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Excellen VL V) as a thermoplastic resin on both sides of the porous body obtained in Example 1
L200) was laminated to a thickness of 50 μm to obtain a drug sustained-release resin molded body. The obtained drug sustained-release resin molded product had excellent performance without bleeding out of the drug onto the surface of the drug sustained-release resin molded product.

(Example 7) A drug sustained-release resin molding was obtained in the same manner as in Example 1 except that the stretching temperature during roll stretching was room temperature (23 ° C). The obtained drug sustained-release resin molded product had good processability and had excellent performance without bleeding out of the drug on the surface of the drug sustained-release resin molded product.

Example 8 Example 1 was repeated except that the amount of the filler was 150 parts by weight, the amount of the drug was 135 parts by weight, and the stretching temperature during roll stretching was room temperature (23 ° C.). A drug sustained-release resin molded product was obtained in the same manner as in (1). The obtained drug sustained-release resin molded product had good processability and had excellent performance without bleeding out of the drug on the surface of the drug sustained-release resin molded product.

Example 9 40 parts by weight of linear low-density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Excellen VL VL200) as a plastic resin and linear low-density polyethylene (manufactured by Sumitomo Chemical Co., Ltd.) Product Name: Sumikasen α
FZ201-0) 60 parts by weight, calcium carbonate (manufactured by Shiraishi Calcium Co., Ltd., trade name: Whiten SSB (red)) 150 parts by weight as a filler, and Hinoki essential oil (manufactured by Kishu Hinokiya Co., Ltd.) as a drug. Using 135 parts by weight,
A drug sustained-release resin molded body was obtained in the same manner as in Example 1 except that the temperature during roll stretching was room temperature (23 ° C.).
The obtained drug sustained-release resin molded product has good processability,
There was no bleed-out of the drug on the surface of the drug sustained-release resin molded product, and it had excellent performance.

(Example 10) The blending amount of the filler was 150 parts by weight, allyl isothiocyanate (Midori Cross Co., Ltd., trade name: Wasa Auro) was used as a drug, and the stretching temperature at the time of roll stretching was room temperature ( 23 ° C) except that
A drug sustained-release resin molded body was obtained in the same manner as in Example 4. The content of allyl isothiocyanate in 100 parts by weight of the drug sustained-release resin molded product was 65 parts by weight. Bleed-out of the drug did not occur on the surface of the obtained drug-controlled release resin molded product, and the drug-controlled release product was good.

Example 11 Pyriproxyfen (manufactured by Sumitomo Chemical Co., Ltd., trade name: Sumilab) was used as a drug.
A drug sustained-release resin molded product was obtained in the same manner as in Example 1, except that 40 parts by weight of d-allethrin (manufactured by Sumitomo Chemical Co., Ltd., trade name: Pinamine Forte) was blended. . The obtained drug sustained-release resin molded product had good processability and had excellent performance without bleeding out of the drug on the surface of the drug sustained-release resin molded product.

Example 12 Pyriproxyfen (manufactured by Sumitomo Chemical Co., Ltd., trade name: Sumilab) was used as a drug.
Parts by weight and methoxydiazone (Sumitomo Chemical Co., Ltd.,
Product name: ELEMIC)
A drug sustained-release resin molded body was obtained in the same manner as in Example 1. The obtained drug sustained-release resin molded product had good processability and had excellent performance without bleeding out of the drug on the surface of the drug sustained-release resin molded product.

(Example 13) 100 parts by weight of linear low-density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Sumikasen α FZ201-0) as a thermoplastic resin and calcium carbonate as a filler (Shiraishi Calcium Co., Ltd. ), Trade name: Whiten SSB (red)) 150 parts by weight, 3 parts by weight of pyriproxyfen as a drug, and phenothrin 36
Parts by weight and N- (2-ethylhexyl) -8,9,10-trinorborn-5-e
A drug sustained-release resin molding was obtained in the same manner as in Example 1 except that 72 parts by weight of ne-2,3-dicarboximide was blended and the stretching temperature during roll stretching was room temperature (23 ° C.). . The obtained drug sustained-release resin molded product had good processability and had excellent performance without bleeding out of the drug on the surface of the drug sustained-release resin molded product.

(Comparative Example 1) 100 parts by weight of linear low-density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Excellen VL VL200) as a thermoplastic resin and calcium carbonate (manufactured by Shiraishi Calcium Co., Ltd.) as a filler, Brand name: Whiten SSB (red) 40 parts by weight and Empentrin (Sumitomo Chemical Co., Ltd., product name: Vaporthrin) 55 parts by weight as a drug are mixed with a Banbury mixer 12
A resin composition was obtained by kneading at 0 ° C. for 5 minutes. This resin composition was formed into a sheet having a thickness of 1 mm by T-die molding with an extruder, and this sheet was stretched uniaxially by 4 times at 50 ° C. with a roll stretching machine to obtain a drug sustained-release resin molded body. Since the obtained drug-releasing resin molded product had a low degree of porosity, empentrin bleeded out from the inside, which was not practical.

(Comparative Example 2) 100 parts by weight of linear low-density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Excellen VL VL200) as a thermoplastic resin and calcium carbonate (manufactured by Shiraishi Calcium Co., Ltd.) as a filler, Brand name: Whiten SSB (red)) 450 parts by weight and Empentrin (Sumitomo Chemical Co., Ltd., product name: Vaporthrin) 55 parts by weight as a drug are mixed with a Banbury mixer 1
A resin composition was obtained by kneading at 2 ° C. for 5 minutes. This resin composition was formed into a sheet having a thickness of 1 mm by T-die molding with an extruder, and this sheet was tried to be stretched 4 times in a uniaxial direction at 50 ° C. with a roll stretching machine, but it broke and was gradually released into a drug-release resin molding. I couldn't get a body.

Comparative Example 3 A resin composition having a thickness of 1 mm was prepared in the same manner as in Example 1 except that the stretching treatment was not performed.
Got a sheet of. Since the obtained sheet was not made porous, empentrin bleeded out from the inside, which was not practical.

(Comparative Example 4) 100 parts by weight of linear low-density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Excellen VL VL200) as a thermoplastic resin and calcium carbonate (manufactured by Shiraishi Calcium Co., Ltd.) as a filler, Trade name: Whiten SSB (red) 120 parts by weight and Empentrin (Sumitomo Chemical Co., Ltd., trade name: Vaporthrin) 55 parts by weight as a medicine by using a Banbury mixer 1
The resin composition was obtained by kneading at 20 ° C. for 5 minutes. This resin composition was formed into a sheet having a thickness of 1 mm by T-die molding with an extruder, and this sheet was tried to be stretched 12 times in a uniaxial direction at 50 ° C. with a roll stretching machine, but it broke, resulting in drug sustained release resin molding. I couldn't get a body.

Example 14 As a thermoplastic resin, 100 parts by weight of linear low-density polyethylene (Sumitomo Chemical Co., Ltd., trade name: Excellen VL VL200, saturated dissolution amount of empentrin 2.3% by weight) and 100 parts by weight of filler Calcium carbonate (Shiraishi Calcium Co., Ltd., trade name: Whiten S
SB (red) 120 parts by weight, and as a drug, Enpentrin (Sumitomo Chemical Co., Ltd., trade name: Vaporthrin,
40 parts by weight of vapor pressure 6.5 × 10 ⁻⁴ mmHg) at 20 ° C. was kneaded with a Banbury mixer at 120 ° C. for 5 minutes to obtain a resin composition. This resin composition was processed into T by an extruder.
A sheet having a thickness of 1 mm was formed by die molding, and the sheet was stretched uniaxially by 4 times at 50 ° C. by a roll stretching machine to obtain a drug sustained-release resin molded body. The amount of drug released from the obtained drug sustained-release resin molded product was measured, and Table 3 and FIG.
As shown in (3), the drug release amount per unit time was controlled to be constant, and it was a very good drug sustained-release resin molded product.

(Example 15) Low density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Sumikasen G80) as a thermoplastic resin on both surfaces of the porous body obtained in Example 14
1) was laminated with a thickness of 50 μm to obtain a drug sustained-release resin molded body. The drug sustained-release resin molded product had excellent performance as shown in Table 3 and FIG.

(Example 16) Linear low density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Excellen VL) on both sides of the porous body obtained in Example 14 as a thermoplastic resin.
VL200) was laminated to have a thickness of 50 μm to obtain a drug sustained-release resin molded body. The drug sustained-release resin molded product had excellent performance as shown in Table 3 and FIG.

(Example 17) High density polyethylene (made by Showa Denko KK, trade name: Shorex 505) as a thermoplastic resin on both sides of the porous body obtained in Example 14
0) was laminated to a thickness of 80 μm to obtain a drug sustained-release resin molding. The drug sustained-release resin molded product had excellent performance as shown in Table 3 and FIG.

Example 18 As a thermoplastic resin, 100 parts by weight of linear low-density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Excellen VL VL200, saturated dissolution amount of allyl isothiocyanate 4.5% by weight) was used. 150 parts by weight of calcium carbonate (manufactured by Shiraishi Calcium Co., Ltd., trade name Whiten SSB (red)) as a filler was kneaded with a Banbury mixer at 120 ° C. for 5 minutes to obtain a resin composition. This resin composition was T-die molded by an extruder to form a sheet having a thickness of 1 mm, and the obtained sheet was allyl isothiocyanate (Midori Cross Co., Ltd., trade name: Wasauro,
4mm uniaxially at room temperature (23 ° C) with a roll stretching machine while immersed in liquid at 20 ° C vapor pressure 4mmHg)
It was stretched twice to obtain a drug sustained-release resin molded product. Furthermore, low-density polyethylene (Sumitomo Chemical Co., Ltd., trade name: Sumikasen F208-0) as a thermoplastic resin was laminated on both sides of this drug sustained-release resin molded product by lamination to a thickness of 50 μm, A molded body was obtained. The drug sustained-release resin molded product had excellent performance as shown in Table 4 and FIG.

(Example 19) This example was prepared in the same manner as in Example 18 except that high-density polyethylene (Showa Denko KK, trade name: SHOWDEX 5050) was used as the thermoplastic resin on both sides. The resin-release molded product had excellent performance as shown in Table 4 and FIG.

(Comparative Example 5) 100 parts by weight of linear low-density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Excellen VL VL200) as a thermoplastic resin and calcium carbonate (manufactured by Shiraishi Calcium Co., Ltd.) as a filler. Brand name: Whiten SSB (red) 40 parts by weight and Empentrin (Sumitomo Chemical Co., Ltd., product name: Vaporthrin) 40 parts by weight as a medicine are mixed with a Banbury mixer 12
A resin composition was obtained by kneading at 0 ° C. for 5 minutes. This resin composition was formed into a sheet having a thickness of 1 mm by T-die molding with an extruder, and this sheet was stretched uniaxially by 4 times at 50 ° C. with a roll stretching machine to obtain a drug sustained-release resin molded body. The obtained drug-releasing resin molded product was not suitable for practical use because the penetrin bleeded out from the inside because of low porosity.

Comparative Example 6 100 parts by weight of linear low density polyethylene (Sumitomo Chemical Co., Ltd., trade name: Excellen VL VL200) as a thermoplastic resin and calcium carbonate (Shiraishi Calcium Co., Ltd.) as a filler, Brand name: Whiten SSB (red) (450 parts by weight) and Empentrin (Sumitomo Chemical Co., Ltd., product name: Vaporthrin) 40 parts by weight as a drug are mixed with a Banbury mixer.
The resin composition was obtained by kneading at 20 ° C. for 5 minutes. This resin composition was formed into a sheet having a thickness of 1 mm by T-die molding with an extruder, and this sheet was tried to be stretched 4 times in a uniaxial direction at 50 ° C. with a roll stretching machine, but it broke and was gradually released into a drug-release resin molding. I couldn't get a body.

(Comparative Example 7) A resin composition having a thickness of 1 m was prepared in the same manner as in Example 14 except that the stretching treatment was not performed.
m sheets were obtained. Since the obtained sheet was not made porous, empentrin bleeded out from the inside, which was not practical.

(Comparative Example 8) 100 parts by weight of linear low-density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Excellen VL VL200) as a thermoplastic resin and calcium carbonate (manufactured by Shiraishi Calcium Co., Ltd.) as a filler, Trade name: 120 parts by weight of Whiten SSB (red) and 40 parts by weight of empentryn (Sumitomo Chemical Co., Ltd., trade name: Vaporthrin) as a drug with a Banbury mixer
The resin composition was obtained by kneading at 20 ° C. for 5 minutes. This resin composition was formed into a sheet having a thickness of 1 mm by T-die molding with an extruder, and this sheet was tried to be stretched 12 times in a uniaxial direction at 50 ° C. with a roll stretching machine, but it broke, resulting in drug sustained release resin molding. I couldn't get a body.

Comparative Example 9 A drug sustained release resin molding was obtained in the same manner as in Example 14 except that the compounding amount of the drug was 2 parts by weight. When the drug release amount from the obtained drug sustained-release resin molded product was measured, the drug release amount per unit time decreased with time as shown in Table 3 and FIG.

(Comparative Example 10) 100 parts by weight of an ethylene-methyl methacrylate copolymer (manufactured by Sumitomo Chemical Co., Ltd., trade name: Acryft WH202, saturated dissolution amount of empentrin 14% by weight) as a thermoplastic resin, and empentrin as a drug. A resin composition was obtained by kneading with 15 parts by weight Banbury mixer at 120 ° C. for 5 minutes. This resin composition was formed into a sheet having a thickness of 1 mm by T-die molding using an extruder to obtain a drug sustained-release resin molded body. When the drug release amount from the obtained drug sustained-release resin molded product was measured, the drug release amount per unit time decreased with time as shown in Table 3 and FIG.

Example 20 100 parts by weight of linear low-density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Excellen VL VL200, saturated dissolution amount of phenothrin 2.2% by weight) as a thermoplastic resin and a filler Calcium carbonate (Shiraishi Calcium Co., Ltd., trade name: Whiten S
SB (red) 120 parts by weight and phenothrin (Sumitomo Chemical Co., Ltd., trade name: Smithlin) 22 parts by weight as a drug were kneaded with a Banbury mixer at 120 ° C. for 5 minutes to obtain a resin composition. This resin composition was formed into a sheet having a thickness of 1 mm by T-die molding with an extruder, and this sheet was stretched uniaxially by 4 times at 50 ° C. with a roll stretching machine to obtain a drug sustained-release resin molded body. The obtained drug-releasing resin molded product had no bleed-out of the drug on the surface, and as shown in Tables 5 and 6, the knockdown effect and the insecticidal effect were very high in initial efficacy and persistence, and the contact type It is an excellent method for sustained release of drugs.

(Example 21) Low density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Sumikasen G80) as a thermoplastic resin on both surfaces of the porous body obtained in Example 20.
1) is laminated to a thickness of 50 μm each,
A drug release resin molding was obtained. The obtained drug sustained-release resin molded product had no bleed-out of the drug on the surface,
Further, as shown in Tables 5 and 6, the knockdown effect and the insecticidal effect have very high initial efficacy and sustainability, and are very excellent as a method for sustained release of a drug.

Example 22 Linear low-density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Excellen VL) as a thermoplastic resin on both surfaces of the porous body obtained in Example 20.
VL200) was laminated to a thickness of 50 μm to obtain a drug sustained-release resin molding. The obtained drug sustained-release resin molded product had no bleed-out of the drug on the surface, and as shown in Tables 5 and 6, the knockdown effect and the insecticidal effect were very high in initial efficacy and persistence. Is an excellent method for the sustained release of

(Example 23) High density polyethylene (manufactured by Showa Denko KK, trade name: Shorex 505) as a thermoplastic resin on both sides of the porous body obtained in Example 20.
0) is laminated to a thickness of 80 μm each,
A drug release resin molding was obtained. The obtained drug sustained-release resin molded product had no bleed-out of the drug on the surface, and Table 5
Also, as shown in Table 6, it was found that the knockdown effect and the insecticidal effect were very high in initial efficacy and persistence, and were extremely excellent as a method for sustained-release of a drug.

(Comparative Example 11) 100 parts by weight of linear low density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Excellen VL VL200) as a thermoplastic resin and calcium carbonate (manufactured by Shiraishi Calcium Co., Ltd.) as a filler, Product name:
40 parts by weight of Whiten SSB (red) and 40 parts by weight of phenothrin (Sumitomo Chemical Co., Ltd., trade name: Smithlin) as a drug are treated with a Banbury mixer at 120 ° C.
Was kneaded for 5 minutes to obtain a resin composition. This resin composition was formed into a sheet having a thickness of 1 mm by T-die molding with an extruder, and this sheet was stretched uniaxially by 4 times at 50 ° C. with a roll stretching machine to obtain a drug sustained-release resin molded body. Since the obtained drug-releasing resin molded product had low porosity, phenothrin bleeded out from the inside, which was not practical.

(Comparative Example 12) 100 parts by weight of linear low-density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Excellen VL VL200) as a thermoplastic resin and calcium carbonate (manufactured by Shiraishi Calcium Co., Ltd.) as a filler, Product name:
450 parts by weight of Whiten SSB (red) and 40 parts by weight of phenothrin (Sumitomo Chemical Co., Ltd., trade name: Smithlin) as a drug were used in 120 by a Banbury mixer.
The resin composition was obtained by kneading at 5 ° C. for 5 minutes. This resin composition was formed into a sheet having a thickness of 1 mm by T-die molding with an extruder, and this sheet was tried to be stretched 4 times in a uniaxial direction at 50 ° C. with a roll stretching machine, but it broke and was gradually released into a drug-release resin molding. I couldn't get a body.

Comparative Example 13 A resin composition having a thickness of 1 was prepared in the same manner as in Example 20 except that the stretching treatment was not performed.
A sheet of mm was obtained. Since the obtained sheet was not made porous, phenothrin bleeded out from the inside, which was not practical.

(Comparative Example 14) 100 parts by weight of linear low density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Excellen VL VL200) as a thermoplastic resin and calcium carbonate (manufactured by Shiraishi Calcium Co., Ltd.) as a filler. Product name:
120 parts by weight of Whiten SSB (red) and 40 parts by weight of phenothrin (Sumitomo Chemical Co., Ltd., trade name: Smithlin) as a drug were used in 120 by a Banbury mixer.
The resin composition was obtained by kneading at 5 ° C. for 5 minutes. This resin composition was formed into a sheet having a thickness of 1 mm by T-die molding with an extruder, and this sheet was tried to be stretched 12 times in a uniaxial direction at 50 ° C. with a roll stretching machine, but it broke, resulting in drug sustained release resin molding. I couldn't get a body.

Comparative Example 15 A drug sustained release resin molding was obtained in the same manner as in Example 20 except that the compounding amount of the drug was 2 parts by weight. The obtained drug sustained-release resin molded product had no bleed-out of the drug on the surface, but as shown in Tables 5 and 6, the knockdown effect and the insecticidal effect were very low.

Comparative Example 16 As a thermoplastic resin, 100 parts by weight of ethylene-methyl methacrylate copolymer (Sumitomo Chemical Co., Ltd., trade name: Acryft WH202, phenothrin saturated dissolution amount 15% by weight), and phenothrin as a drug 1 by 15 parts by weight Banbury mixer
The resin composition was obtained by kneading at 20 ° C. for 5 minutes. This resin composition was formed into a sheet having a thickness of 1 mm by T-die molding using an extruder to obtain a drug sustained-release resin molded body. The obtained drug-releasing resin molded product did not bleed out the drug to the surface, but as shown in Tables 5 and 6, the knockdown effect and insecticidal effect were very low.

(Comparative Example 17) As a thermoplastic resin, vinyl chloride (manufactured by Sumitomo Chemical Co., Ltd., trade name: Smilit)
Sx-13F) 100 parts by weight, DOA43 as a plasticizer
By weight, 25 parts by weight of phenothrin as a drug was kneaded by roll kneading for 5 minutes to obtain a resin composition. This resin composition was formed into a sheet having a thickness of 1 mm by T-die molding using an extruder to obtain a drug sustained-release resin molded body. The obtained drug sustained-release resin molded product had no drug bleed-out on the surface, and
The initial efficacy was high as shown in Table 1, but the persistence of efficacy was very low as shown in Table 6.

Example 24 100 parts by weight of linear low density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Excellen VL VL200) as a thermoplastic resin and calcium carbonate (manufactured by Shiraishi Calcium Co., Ltd.) as a filler, Product name:
450 parts by weight of Whiten SSB (red) and 55 parts by weight of empentryn (Sumitomo Chemical Co., Ltd., trade name: Vaporthrin) as a drug are kneaded with a Banbury mixer at 120 ° C. for 5 minutes to obtain a resin composition. It was This resin composition was formed into a strand having a diameter of 1 mm by an extruder, and the strand was cut with a drawing die having a 600 μm opening.
A drug sustained-release resin molded product was obtained by uniaxially stretching 4 times at 3 ° C.

Example 25 100 parts by weight of linear low-density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Excellen VL VL200) as a thermoplastic resin and calcium carbonate (manufactured by Shiraishi Calcium Co., Ltd.) as a filler, Product name:
100 parts by weight of Callite SA) was kneaded with a Banbury mixer at 120 ° C. for 5 minutes to obtain a resin composition. This resin composition was formed into a sheet having a thickness of 1.6 mm by T-die molding with an extruder, and this sheet was stretched 4 times uniaxially at 23 ° C. with a roll stretching machine to obtain a porous resin molded sheet. The obtained sheet was immersed in an allyl isothiocyanate (manufactured by Midori Cross Co., Ltd., trade name: Wasauro, vapor pressure 4 mmHg at 20 ° C.) liquid, and the absorption amount of allyl isothiocyanate was measured with time. Start soaking 30
Since the weight reached a certain value after a minute, the sheet was pulled up and the allyl isothiocyanate adhering to the surface was wiped off to obtain a drug sustained-release resin molded body.

[0061]

[0062]

[0063]

Resin A: Linear low-density polyethylene (manufactured by Sumitomo Chemical Co., Ltd., trade name: Excellen VL VL20)
0, comonomer: butene-1, density 0.900 g / cm
³ ) Resin B: Linear low density polyethylene (Sumitomo Chemical Co., Ltd.)
Product name: Sumikasen α CS3003, comonomer: hexene-1, density 0.933 g / cm ³ ) Resin C: low density polyethylene (Sumitomo Chemical Co., Ltd.,
Product name: Sumikasen F208-0, density 0.933g
/ Cm ³ ) Resin D: Low density polyethylene (manufactured by Sumitomo Chemical Co., Ltd.,
Product name: Sumikasen G801) Resin E: Linear low density polyethylene (Sumitomo Chemical Co., Ltd.)
Made, trade name: Sumikasen α FZ201-0, comonomer: hexene-1, density 0.912 g / cm ³ ) Resin F: ethylene-methyl methacrylate copolymer (Sumitomo Chemical Co., Ltd. make, trade name: Acryft WH20
2) Resin G: High-density polyethylene (Showa Denko KK, trade name: Shorex 5050) Resin H: Vinyl chloride (Sumitomo Chemical Co., Ltd., trade name:
Smilit Sx-13F) Filler: calcium carbonate (manufactured by Shiraishi Calcium Co., Ltd., trade name: Whiten SSB (red)), * indicates calcium carbonate (manufactured by Shiraishi Calcium Co., Ltd., trade name: Callite S)
A) Drug a: Empentrin (Sumitomo Chemical Co., Ltd., trade name: Vaporthrin) Drug b: Phenotrin (Sumitomo Chemical Co., Ltd., trade name: Smith Lin) Drug c: Hinoki essential oil (Kishu Hinokiya) Drug d: allyl isothiocyanate (Midori Cross Co., Ltd.)
Made, trade name: Wasauro) Drug e: Pyriproxyfen (Sumitomo Chemical Co., Ltd.,
Trade name: Sumilab) Drug f: d-allethrin (Sumitomo Chemical Co., Ltd., trade name: Pinamine Forte) Drug g: Methoxydiazone (Sumitomo Chemical Co., Ltd., trade name: Elemic) Drug h: MGK264

Evaluation of processability and bleed-out Examples 1-3, 5, 6, 14-17, 20-23 were carried out at 50 ° C. in air, and in Example 4 at 50 ° C. in drug, Example 7- 13, 18, 19, 24, 25 are in air / 23 ° C
As a result of stretching at a magnification of 4 times, the workability is good,
No bleed out was seen from the resulting product.

[0066]

[0067]

[0068]

[0069]

[0070]

[0071]

[Brief description of drawings]

FIG. 1 shows the transpiration rate of the agents of Examples 14-17 and Comparative Examples 9 and 10 (Table 3) over time.

FIG. 2 shows the transpiration rate of the drug of Example 18 (Table 4) over time.

FIG. 3 shows the transpiration rate with time of the drug of Example 19 (Table 4).

─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. ⁶ Identification number Office reference number FI technical display location // B29K 105: 16 (31) Priority claim number Japanese Patent Application No. 5-7463 (32) Priority Sundaira 5 (1993) January 20 (33) Priority claiming country Japan (JP) (31) Priority claim number Japanese Patent Application No. 5-122431 (32) Priority Date 5 (1993) May 25 (33) Priority Claiming country Japan (JP)

Claims (12)

[Claims] 1. A thermoplastic resin 100 parts by weight and a filler 50 to 50 parts by weight.
A porous resin molding obtained by uniaxially or biaxially stretching a resin composition consisting of 400 parts by weight at a ratio of 1.1 to 10 contains a drug in an amount equal to or more than a saturated dissolution amount in a thermoplastic resin. Drug sustained release resin molding. 2. The drug sustained-release resin molded article according to claim 1, wherein the drug sustained-release resin molded article is a film or a sheet. 3. The drug sustained-release resin molded article according to claim 1, wherein the drug sustained-release resin molded article is a rod-shaped body. 4. A drug sustained-release resin molded product comprising a drug-permeable thermoplastic resin composition layer arranged on at least one surface of the drug sustained-release resin molded product according to claim 2. 5. A drug sustained-release resin molded product comprising a drug-permeable thermoplastic resin composition layer on the outer periphery of the drug sustained-release resin molded product according to claim 3. 6. The thermoplastic resin is a polyolefin resin, the drug is one or more of an insect repellent, a repellent, a bactericide, a fungicide, and an aromatic, and the filler is calcium carbonate. 6. The drug sustained-release resin molded product according to any one of claims 1 to 5. 7. The controlled drug release molded article according to claim 6, wherein the drug is at least one insect repellent selected from the group consisting of pyrethroid insecticides, methoxydiazone, and pyriproxyfen. 8. The polyolefin resin is ethylene and C
The drug-controlled release resin molded article according to claim 6 or 7, which is a copolymer with at least one α-olefin selected from _3- C ₁₈ α-olefins. 9. A thermoplastic resin 100 parts by weight and a filler 50 to 50 parts by weight.
A drug sustained-release resin comprising a resin composition comprising 400 parts by weight and an amount of a drug having a saturated solubility or higher with respect to a thermoplastic resin, which is uniaxially or biaxially stretched at a ratio of 1.1 to 10 to be porous. Method for manufacturing molded body. 10. A thermoplastic resin 100 parts by weight and a filler 50.
The resin composition consisting of ˜400 parts by weight is uniaxially or biaxially 1.1 to 10 in the state of being dipped in the chemical or coated with the chemical.
A method for producing a drug sustained-release resin molded product, which comprises stretching twice and making it porous. 11. A thermoplastic resin 100 parts by weight and a filler 50.
To 400 parts by weight of a resin composition uniaxially or biaxially stretched at a ratio of 1.1 to 10 to contain a drug in an amount equal to or higher than its saturated solubility in a thermoplastic resin. A method for producing a characterized drug sustained-release resin molded product. 12. A thermoplastic resin 100 parts by weight and a filler 50.
To 400 parts by weight of a resin composition uniaxially or biaxially stretched at a ratio of 1.1 to 10, and a group consisting of a pyrethroid insecticide, methoxydiazone, and pyriproxyfen. A method for controlling insect pests, which comprises using a drug sustained-release resin molded product containing at least one or more insect repellents selected from the above, in an amount of saturated solubility or higher in a thermoplastic resin.